Complement-targeted therapeutics
Article Abstract:
The current therapeutic strategies are discussed by focusing on complement-targeted drug candidates that are in clinical trials or in late preclinical development. The approval of eculizumab has validated the complement system as therapeutic target and it might facilitate clinical development of other potential drug candidates.
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
Clinical trials
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Weighing the outcomes
Article Abstract:
The issue of increasing evaluation of their overall healthcare value by the healthcare payers, its subsequent results and the steps to be taken by the drug manufacturers are discussed.
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2008
HEALTH SERVICES, Health care industry
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2008
User Contributions:
Comment about this article or add new information about this topic:
Subjects list: United States, Management, Pharmaceutical industry, Company business management
Similar abstracts:
- Abstracts: The biotech company view. Becoming an American company: A holistic approach to decision making. Sidney Wolfe
- Abstracts: Research issues in building brand equity and global brands in the pc market. part 2 Involving stakeholders in developing corporate brands: the communication dimension
- Abstracts: Pioneering advantage and product-country image: evidence from an exploratory study in China. Market-based organizational learning-theoretical reflections and conceptual insights
- Abstracts: Effect of stiffness and movement speed on selected dynamic torque characteristic of hydraulic-actuation joystick controls for heavy vehicles
- Abstracts: Monoclonal expand into neural disorders. Ann Arbor community rallies in wake of Pfizer shutdown. Incretin mimetics vie for slice of type 2 diabetes market
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.